HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

RELATED LINKS
Free Membership
Premium Home
Zacks #1 Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
Mutual Funds
ETFs
RSS Feed
Profit from the Pros
Subscription Services
FTM Trader
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


GPRO: GEN-PROBE INC - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

GEN-PROBE INC (NASD)
GPRO 81.19 -0.01 (-0.01%) Vol.  379,952 16:00 ET

Zacks Rank: 3 - Hold

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 81.16 - 81.28
52wk Low - High 53.92 - 82.59
Avg Volume 2,259,608
Industry MED-BIOMED/GENE
Market Cap 3.67 B
Div - Yield 0.00 - 0.00
PE (forward) 31.02
PEG Ratio 2.31
Current Year Est. 2.62
EPS Last Year 2.35
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
3 - Hold
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 05/23/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
GEN-PROBE INC GPRO 3
AFFYMAX INC AFFY 1
AGENUS INC AGEN 1
HESKA CORP HSKA 1
Top Peer Analysis Zacks Premium
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.75
ABR (Last Week) 2.75
# of Recs in ABR 16
Average Target Price 79.16
Rank in Industry 151 out of 176
More Brokerage Recommendations


NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate GPRO?

Buy Sell
Find out what the Zacks Community
thinks of GPRO at PeopleAndPicks.com
 
ZACKS COMMENTARY FOR GPRO
Zacks Blog: Gen-Probe Remains Neutral
May 25, 2012
Zacks Equity Research: Report for GPRO
May 23, 2012
Zacks Blog: FDA Approves Gen-Probe's PANTHER
May 11, 2012
Zacks Blog: Earnings Scorecard: Hologic
May 10, 2012
Zacks Blog: Qiagen Expands Its Points of Need
May 07, 2012
Zacks Blog: Gen-Probe's EPS and Sales Beat
May 02, 2012
Zacks Blog: HOLX / GPRO Deal Could Be Good for CUR
May 01, 2012
Zacks Blog: Hologic Incurs Loss, Eyes Gen-Probe
May 01, 2012
More Zacks Commentary
NEWS
Gen-Probe Has Returned 17.9% Since SmarTrend Recommendation (GPRO)
May 24, 2012
Best Relative Performance in the Office REITs Industry Detected in Shares of Digital Realty Trust (DLR, BDN, DEI, BMR, LXP) - Story Title - Comtex
May 24, 2012
Top 5 Companies in the Health Care Equipment Industry with the Best Relative Performance (MAKO, NXTM, SYK, GPRO, IDXX)
May 23, 2012
Shares of Lexington Realty Trust Underperformed its Peers in the Office REITs Industry (LXP, CLI, BDN, BMR, BXP) - Story Title - Comtex
May 23, 2012
MAKO Surgical has Relatively Underperformed its Peers in the Health Care Equipment Industry (MAKO, WMGI, GPRO, BSX, CFN)
May 22, 2012
Post Earnings Update: Gen-Probe Has Sunk 1.1% Lower in Past 2 Weeks (GPRO)
May 19, 2012
Gen-Probe Shares Up 17.4% Since SmarTrend's Buy Recommendation (GPRO)
May 17, 2012
Gen Probe (GPRO) Showing Bullish Technicals With Resistance At $81.56
May 17, 2012
More News
EARNINGS ESTIMATES
  This Quarter
06/2012
Next Quarter
09/2012
This Year
12/2012
Next Year
12/2013
Average Estimate 0.58 0.67 2.62 2.97
Number of Estimates 17 17 17 17
Low Estimates 0.54 0.61 2.53 2.74
High Estimate 0.61 0.72 2.73 3.34
Year Ago EPS 0.51 0.57 2.34 2.62
EPS Growth 13.15% 17.44% 11.87% 13.51%

More Estimates

COMPANY DESCRIPTION
Gen-Probe Inc. is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing (NAT) products used for the clinical diagnosis of human diseases and for screening donated human blood. Using its patented NAT technology, Gen-Probe has received FDA approvals for more than 40 products that detect a wide variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections.

Full Company Report
FINANCIALS
EPS TTM 2.35
Sales 576.23
Net Income 49.31
Price/Earnings 34.55
Price/Book 4.92
Price/Cash Flow 22.33
Price/Sales 6.26


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research